Analgesic and anti-inflammatory drug use and risk of bladder cancer: A population based case control study

BMC Urology

Volumn 7, Issue , 2007, Pages

  Fortuny, Joan ^a   Kogevinas, Manolis ^a   Zens, Michael S ^b   Schned, Alan ^b   Andrew, Angeline S ^b   Heaney, John ^b   Kelsey, Karl T ^c   Karagas, Margaret R ^b  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENACETIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG USE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; RISK; BLADDER TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; HEALTH SURVEY; METHODOLOGY; MIDDLE AGED; RISK FACTOR;

AGED; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 35348882103     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-7-13     Document Type: Article

References (38)

1. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Ferlay F Bray P Pisani D Parkin, IARC Press 2001
2. Bladder cancer. DT Silverman SS Devessa LF Moore N Rothman, Cancer Epidemiology and Prevention 2005
3. Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma. BG Volkmer EM Seidl-Schlick D Bach I Romics K Kleinschmidt, Clin Rheumatol 2005 24 4 319 323 10.1007/s10067-004-1032-2 16034647
4. Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42. IARC, Lyon: International Agency for Research on Cancer 1987 7
5. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. M McCredie JH Stewart JM Ford RA MacLennan, Br J Uurol 1983 55 2 220 224
6. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. JM Piper J Tonascia GM Matanoski, N Engl J Med 1985 313 5 292 295 4010740
7. Phenacetin abuse related to bladder cancer. W Fokkens, Environ Res 1979 20 1 192 198 10.1016/0013-9351(79)90097-5 499168
8. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. JE Castelao JM Yuan M Gago-Dominguez MC Yu RK Ross, Br J Cancer 2000 82 7 1364 1369 10.1054/bjoc.1999.1106 10755416
9. Regular use of analgesics is a risk factor for renal cell carcinoma. M Gago-Dominguez JM Yuan JE Castelao RK Ross MC Yu, Br J Cancer 1999 81 3 542 548 10.1038/sj.bjc.6690728 10507783
10. Does paracetamol cause urothelial cancer or renal papillary necrosis? M McCredie JH Stewart, Nephron 1988 49 4 296 300 3412544
11. Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. W Pommer E Bronder A Klimpel U Helmert E Greiser M Molzahn, Nephrol Dial Transplant 1999 14 12 2892 2897 10.1093/ndt/14.12.2892 10570093
12. Tumours of the renal pelvis and ureter. Observations in 170 patients. J Steffens R Nagel, Br J Urol 1988 61 4 277 283 3289673
13. Acetaminophen and renal and bladder cancer. LE Derby H Jick, Epidemiology 1996 7 4 358 362 10.1097/00001648-199607000-00004 8793360
14. Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. S Friis GL Nielsen L Mellemkjaer JK McLaughlin AM Thulstrup WJ Blot L Lipworth H Vilstrup JH Olsen, Int J Cancer 2002 97 1 96 101 10.1002/ijc.1581 11774249
15. Acetaminophen and the risk of renal and bladder cancer in the general practice research database. JA Kaye MW Myers H Jick, Epidemiology 2001 12 6 690 694 10.1097/00001648-200111000-00018 11679798
16. Risk factors for renal cell carcinoma: results of a population-based case-control study. N Kreiger LD Marrett L Dodds S Hilditch GA Darlington, Cancer Causes Control 1993 4 2 101 110 10.1007/BF00053150 8481488
17. International renal-cell cancer study. II. Analgesics. M McCredie W Pommer JK McLaughlin JH Stewart P Lindblad JS Mandel A Mellemgaard B Schlehofer S Niwa, Int J Cancer 1995 60 3 345 349 7829242
18. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. M McCredie JH Stewart NE Day, Int J Cancer 1993 53 2 245 249 10.1002/ijc.2910530212 8425761
19. Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States). L Rosenberg RS Rao JR Palmer BL Strom A Zauber ME Warshauer PD Stolley S Shapiro, Cancer Causes Control 1998 9 1 83 88 10.1023/A:1008805505154 9486467
20. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. MJ Langman KK Cheng EA Gilman RJ Lancashire, BMJ 2000 320 7250 1642 1646 10856067 10.1136/bmj.320. 7250.1642
21. Aspirin use and chronic diseases: a cohort study of the elderly. A Paganini-Hill A Chao RK Ross BE Henderson, BMJ 1989 299 6710 1247 1250 2513898
22. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. KV Rao CJ Detrisac VE Steele ET Hawk GJ Kelloff DL McCormick, Carcinogenesis 1996 17 7 1435 1438 10.1093/carcin/17.7.1435 8706245
23. Aspirin use and mortality from cancer in a prospective cohort study. LD Ratnasinghe BI Graubard L Kahle JA Tangrea PR Taylor E Hawk, Anticancer Res 2004 24 5B 3177 3184 15510608
24. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. HT Sorensen S Friis B Norgard L Mellemkjaer WJ Blot JK McLaughlin A Ekbom JA Baron, Br J Cancer 2003 88 11 1687 1692 10.1038/sj.bjc.6600945 12771981
25. Aspirin use and risk of fatal cancer. MJ Thun MM Namboodiri EE Calle WD Flanders CW Heath Jr, Cancer Res 1993 53 6 1322 1327 8443812
26. A population-based study of immunohistochemical detection of p53 alteration in bladder cancer. KT Kelsey T Hirao A Schned S Hirao T Devi-Ashok HH Nelson A Andrew MR Karagas, Br J Cancer 2004 90 8 1572 1576 10.1038/sj.bjc.6601748 15083187
27. Recall accuracy for prescription medications: self-report compared with database information. SL West DA Savitz G Koch BL Strom HA Guess A Hartzema, Am J Epidemiol 1995 142 10 1103 1112 7485055
28. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. J Fortuny M Kogevinas M Garcia-Closas FX Real A Tardon R Garcia-Closas C Serra A Carrato J Lloreta N Rothman, Cancer Epidemiol Biomarkers Prev 2006 15 9 1696 1702 10.1158/1055-9965.EPI-06-0038 16985032
29. Acetaminophen down-regulates interleukin-1beta-induced nuclear factor-kappaB nuclear translocation in a human astrocytic cell line. F Mancini C Landolfi M Muzio L Aquilini L Soldo I Coletta A Guglielmotti A Mantovani M Pinza C Milanese, Neurosci Lett 2003 353 2 79 82 10.1016/j.neulet.2003.08.074 14664905
30. [Expression of NF-kappa B in human bladder cancer and its clinical significance]. DH Xie XD Tang SJ Xia JM Tan XH Wang Y Cai, Ai Zheng 2002 21 6 663 667 12452071
31. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. SU Ruepp RP Tonge J Shaw N Wallis F Pognan, Toxicol Sci 2002 65 1 135 150 10.1093/toxsci/65.1.135 11752693
32. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. SM de Morais JP Uetrecht PG Wells, Gastroenterology 1992 102 2 577 586 1732127
33. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Y Takada A Bhardwaj P Potdar BB Aggarwal, Oncogene 2004 23 57 9247 9258 15489888
34. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications]. C Wulfing E Eltze D Von Struensee P Wulfing ME Bode O Bettendorf H Piechota L Hertle, Aktuelle Urol 2004 35 4 331 338 10.1055/s-2004-818537 15459875
35. COX-2: a molecular target for colorectal cancer prevention. JR Brown RN DuBois, J Clin Oncol 2005 23 12 2840 2855 10.1200/JCO.2005.09.051 15837998
36. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. PJ Wild LA Kunz-Schughart R Stoehr M Burger H Blaszyk R Simon T Gasser M Mihatsch G Sauter A Hartmann, Int J Oncol 2005 27 2 385 391 16010419
37. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. NR Cook IM Lee JM Gaziano D Gordon PM Ridker JE Manson CH Hennekens JE Buring, JAMA 2005 294 1 47 55 10.1001/jama.294.1.47 15998890
38. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. DM Schreinemachers RB Everson, Epidemiology 1994 5 2 138 146 10.1097/00001648-199403000-00003 8172988